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Objectives:  To determine  if birth month  has an  effect  on  the  incidence  of  adverse  events  following  the 2-
and  12-month  recommended  vaccinations.
Study  design:  Using  health  administrative  databases,  we  conducted  a population-based  retrospective
cohort  study  and  employed  a  self-controlled  case  series  analysis  approach.  We  included  children  born  in
Ontario, Canada  between  April  1st 2002  and  March  31st  2010  who  received  the  diphtheria,  tetanus,  per-
tussis,  inactivated  poliovirus  and Haemophilus  inﬂuenzae  type  b (DTaP-IPV-Hib)  vaccine  recommended
at  2  months  and/or  the  measles,  mumps,  and  rubella  vaccine  recommended  at 12  months.  We  calcu-
lated  the  relative  incidence  (RI)  of  hospitalizations  and emergency  room  visits  within  a pre-speciﬁed  risk
period  compared  to a control  period  following  vaccination.  We  measured  the  effect of  birth  month  using
relative  incidence  ratios  (RIRs)  to  compare  the  RI for infants  born  in  each  month  to  that  for  the month
having  the  lowest  RI.
Results:  For  the  2-month  vaccination,  we observed  the  lowest  and  highest  RIs  for  infants  born  in October
and  April,  respectively.  The  RIR  (95%  CI) for April  compared  to October  was  2.06  (1.59–2.67,  p  <  0.0001),
consistent  with  a strong  seasonal  effect.  For  the  12-month  vaccination,  November  births  had  the  lowest
RI, whereas  August  births  had  the  highest.  The  RIR (95%  CI)  for August  compared  to  November  was  1.52
(1.30–1.77,  p  < 0.0001).
Conclusions:  Our  ﬁndings  suggest  a  seasonal  effect  on susceptibility  to adverse  events  following  vac-
cination  exists.  Further  study  will  be  important  to  elucidate  potential  biological  and/or  behavioral
explanations  for the seasonal  effect  we  observed.
ublis©  2014  The  Authors.  P
. IntroductionAdverse events following immunization (AEFI) are reactions or
ther events that occur after receiving a vaccine, which may  or
Abbreviations: RI, relative incidence; RIR, relative incidence ratio; ICES, Institute
or  Clinical Evaluative Sciences; ER, emergency room; 95% CI, 95% conﬁdence inter-
als; AEFI, adverse events following immunization; MMR,  measles, mumps, rubella;
CCS, self-controlled case series; UV, ultraviolet.
∗ Corresponding author at: The Ottawa Hospital, Civic Campus, 1053 Carling
venue, Box 684, Ottawa, Ontario K1Y 4E9, Canada. Tel.: +1 613 798 5555x17921;
ax: +1 6137615402.
E-mail address: kwilson@ohri.ca (K. Wilson).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.059
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
may  not be causally related to the vaccination. Increased incidence
of AEFIs among subgroups of individuals could help to identify vul-
nerable subpopulations of children and/or issues with the safety
proﬁle of a vaccine.
In previous work we  reported a signiﬁcant increase in ER vis-
its and acute admissions to hospital following measles, mumps
and rubella (MMR)  vaccination recommended at 12 and 18
months of age [1]. For the recommended 2-, 4- and 6-month
diphtheria, tetanus, acellular pertussis, inactivated poliovirus and
Haemophilus inﬂuenza type b, inactivated poliovirus (DTaP-IPV-
Hib) vaccinations, we  found no increase in admissions and ER visits
in the post-vaccination period [2]. Using methods developed in our
previous work, we have identiﬁed a number of risk factors that may
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ncrease susceptibility to AEFI, including birthweight at term [3],
rematurity [4], socioeconomic status [5], sex [6] and birth order
7]. Additionally, a number of studies have reported that the sea-
on of birth affects the risk of immune-mediated diseases such as
ultiple sclerosis, type I diabetes and inﬂammatory bowel disease
8–11]. Seasonal factors could act in the perinatal period, or well
efore this, through environmental and epigenetic inﬂuences dur-
ng gestation that may  affect embryonic and fetal tissue structure
uring development [12,13]. The seasonal inﬂuence that has been
hown for immune-mediated diseases could potentially translate
nto an effect of month of birth on rates of AEFI during the ﬁrst
ear of life. In this study, we addressed this question by assessing
he association between month of birth and the relative incidence
RI) of AEFI, deﬁned as hospital admissions or ER visits, following
accination.
. Methods
.1. Study population
Children born in Ontario between April 1st 2002 and March
1st 2010 who were enrolled in the Ontario Health Insurance Plan
OHIP) were eligible for inclusion in the study cohort. OHIP is
ntario’s universal health insurance plan which covers nearly all
ntario residents. We  excluded multiple births, infants born pre-
aturely (<37 weeks gestation) and infants in the bottom decile
f birth weight for their gestational age. After these exclusions,
nfants who were vaccinated at 2 and/or 12 months of age were
ncluded in the study cohort. We  excluded children who  died, or
hose follow-up was otherwise terminated before the end of the
equired observation period (Supplementary Fig. 1).
.2. Vaccinations
As part of the publicly funded immunization schedule in
ntario, Canada, vaccinations given at 2, 4 and 6 months of age
ncluded those against pertussis, diphtheria, tetanus and polio
nd Haemophilus inﬂuenzae type b (cPDT Polio + Hib until January
005; DTaP-IPV-Hib thereafter). As of January 2005, a pneumo-
occal vaccine was also administered at 2, 4, and 6 months of age
Pneu-C-7 until October 2009; Pneu-C-10 thereafter). The ﬁrst dose
f the measles, mumps  and rubella vaccine (MMR) was  given at
2 months of age throughout the entire study period, and as of
eptember 2004, a vaccine against meningococcal disease (type C)
as added to the schedule [14].
.3. Data sources
All study data were linked using unique, encoded identiﬁers
nd analyzed at the Institute for Clinical Evaluative Sciences (ICES).
e identiﬁed vaccinations from the OHIP database using general
accination billing codes and methods described previously [1,2].
o identify the 2-month vaccinations, we selected those occurring
n the exact recommended date (60 days) and up to two  weeks
efore or up to one month after. For the 12-month vaccination, we
elected those occurring at 365 days of age, as well as up to 60 days
ast that date. We  ascertained hospital admissions using the Cana-
ian Institute for Health Information’s (CIHI’s) Discharge Abstract
atabase (DAD), and ER visits using CIHI’s National Ambulatory
are Reporting System (NACRS). The Registered Persons Database
as used to ascertain eligibility for OHIP coverage and deaths. We
eﬁned our composite primary outcome as all-cause ER visits and
dmissions, with the a priori exclusion of events having diagnoses
hat could not reasonably be causally associated with vaccination2 (2014) 7148–7153 7149
(Supplementary Table 1). Ethical approval for this study was
obtained from The Ottawa Hospital Research Ethics Board.
2.4. Design and analysis
The analysis was conducted using the self-controlled case series
(SCCS) design [15,16] and the Vaccine and Immunization Surveil-
lance in Ontario (VISION) analytic architecture [17]. Our general
analytical strategy has been described in detail elsewhere [1,2].
We were primarily interested in adverse events following ﬁrst vac-
cine exposure at two  months (cPDT Polio + Hib or DTaP-IPV-Hib),
and ﬁrst exposure to MMR  vaccine at 12 months of age. Therefore,
we selected observation periods that biologically relate to these
exposures. For the 2-month vaccination, we  designated the 48 h
post-vaccination (days 0–1) as the risk period and days 9–18 as the
control period. At 12 months, the risk period included days 8–12
post-vaccination and the control period included days 20–28. These
risk periods were modiﬁed a priori from our previous studies to
include only the time of most intense excess event incidence.
In many instances, acute admissions immediately follow an ER
visit (i.e. a patient presents to the ER and requires admission). We
counted only the ﬁrst event to occur in a risk or control period,
thus avoiding the need to decide whether events close together in
occurrence truly were distinct, or part of the same ‘episode’ of care.
We calculated the RI of the primary endpoint in the risk period
compared to the control period using a conditional Poisson regres-
sion model, which included terms for exposure period and for
identifying each individual child, thereby accounting for intra-
individual correlation and allowing each individual to serve as
his/her own  control. To illustrate the magnitude of the effect of
birth month on the RI of our endpoint, we  computed relative inci-
dence ratios (RIRs) by comparing the RI of events in infants born
in each month to that for the month having the lowest RI. This
was identiﬁed post hoc. A test for interaction between risk period
and month of birth was used to establish statistical signiﬁcance of
differences in RIs between birth month subgroups [16].
To test for the presence of a cyclical seasonal pattern in RIs, we
repeated the SCCS analysis at both the 2- and 12-month vaccina-
tion with the season effect parameterized using a cosinor modeling
approach [18]. Details of the cosinor model implementation are
provided in the Supplemental Methods.
All p-values were two-sided, and all analyses were conducted
using SAS version 9.2 (SAS Institute, Cary, NC).
2.5. Sensitivity analyses
2.5.1. Analysis of individual years
In order to determine whether the effect of season was similar
across individual calendar years, we  repeated our analysis for each
year separately from 2002 to 2010.
2.5.2. Original versus restricted risk periods
To determine the impact of using risk periods restricted to days
0 and 1 for 2-month vaccinations and days 8–12 for 12-month vac-
cinations as compared to risk periods from past studies (days 0–2
and days 4–12, respectively), we conducted our analysis by birth
month using both risk period deﬁnitions.
2.5.3. Event incidences in risk and control periods
In order to investigate whether effects of birth month were pri-marily driven by differences in (a) the risk periods or (b) the control
periods, we  computed ratios comparing the incidences of events in
risk periods between each birth month and the reference month
(relative risk incidence) and similarly, the incidences of events in
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Fig. 1. Relative incidence of events and 95% conﬁdence intervals following the 2-
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We  investigated the impact of month of birth on the relativeonth vaccination for each birth month.
ontrol periods between each birth month and the reference month
relative control incidence).
. Results
Data were available for 1,074,060 newborns from April 1st,
002 to March 31st 2010, representing virtually every child
orn in Ontario during that period. Of these infants, 729,957
nfants received the 2-month vaccination and 625,255 received
he 12-month vaccination (Supplementary Fig. 1). 572,511 infants
eceived both the 2- and 12-month vaccinations. Supplementary
able 2 presents socio-demographic information for infants who
eceived the 2-month vaccination, by month of birth. Although sta-
istically signiﬁcant due to high statistical power, the magnitudes of
bserved differences for characteristics of vaccinated infants across
irth months were too small to be of clinical signiﬁcance.
.1. 2-Month vaccination
The overall RI of ER visits and hospitalizations following the 2-
onth vaccination was 0.76 (95% CI: 0.72–0.80). There was strong
vidence of differences in RI across birth months (p < 0.0001 for
nteraction) (Table 1 and Fig. 1). We  observed the lowest RI of events
or infants born in October (RI (95% CI): 0.51 (0.43–0.62)), and the
ighest RI for children born in April (RI (95% CI): 1.07 (0.89–1.28)).
he RIR (95% CI) for April compared to October was 2.06 (1.59–2.67).
he cosinor test for seasonality was highly statistically signiﬁcant
p < 0.0001).
.2. 12-Month vaccination
For the 12-month vaccination, the overall RI (95% CI) was 1.70
1.65–1.75). Infants born in November had the lowest RI of events
RI (95% CI): 1.39 (1.25–1.54)), whereas July births had the highest
I of events (RI (95% CI): 2.11 (1.89–2.36); Table 1 and Fig. 2). The
IR (95% CI) for July compared to November was 1.52 (1.30–1.77).
he cosinor test for seasonality was highly statistically signiﬁcant
p = 0.0002).Fig. 2. Relative incidence of events and 95% conﬁdence intervals following the 12-
month vaccination for each birth month.
3.3. Event types observed during the post-vaccination risk period
at 2 and 12 months
The events we observed were overwhelmingly comprised of
low acuity emergency room visits. International Classiﬁcation of
Diseases (ICD-10) codes for the most responsible diagnosis were
examined and were largely made up of complaints such as upper
respiratory infections, fever, rash, otitis media, vomiting and gas-
troenteritis. For both the 2- and 12-month vaccinations, the top
10 main diagnoses (ICD-10 codes and descriptions) for events that
occurred in the risk period following vaccination in the months of
highest and lowest RI of ER visits and admissions are reported in
Supplementary Table 3.
3.4. Sensitivity analyses
3.4.1. Analysis of individual years
For the analysis by month of birth, we found a very similar
cyclical pattern of RI for both the 2- and 12-month recommended
vaccinations in the vast majority of individual years included in the
study.
3.4.2. Original versus restricted risk periods
While we  observed the same cyclical pattern of RI by birth
month for the original wider risk intervals compared to the
restricted intervals deﬁned in the current study, the effect sizes
were more muted for both the 2- and 12-month vaccinations.
3.4.3. Event incidences in risk and control periods
For the 2-month vaccination, the highest relative risk incidence
was observed in April births, the same month as the highest RIR.
However, one of the lowest relative control incidences was  also
observed for infants born in April, suggesting that both of these
effects were important factors in driving the seasonal pattern
observed at the 2-month vaccination (Table 1). For the 12-month
vaccination, the birth month with the highest RIR was  July, which
corresponded to the month in which the lowest relative control
incidence occurred. However, the relative risk incidence peaked
earlier, in March.
4. Discussionincidence of AEFI using ER visits and hospital admissions as a proxy.
Our study is, to the best of our knowledge, the ﬁrst to describe
S. Hawken et al. / Vaccine 32 (2014) 7148–7153 7151
Table  1
2- and 12-month vaccination.
Birth month Number of
infants
vaccinated
Events in risk
period
Events in
control period
Relative
incidence (95%
CI)
Relative
incidence ratio
(95% CI)
Relative risk
incidence
Relative
control
incidence
p-value
2-Month vaccination
Overall 729,957 1559 9264 0.76 (0.72,0.80) –
Jan 58,191 117 827 0.64 (0.52,0.77) 1.23 (0.94,1.61) 0.95 0.77
Feb  54,989 121 703 0.77 (0.64,0.94) 1.50 (1.15,1.96) 0.98 0.66
Mar  61,573 118 660 0.80 (0.66,0.98) 1.56 (1.19,2.04) 0.96 0.62
Apr  61,322 147 621 1.07 (0.89,1.28) 2.06 (1.59,2.67) 1.20 0.58
May  63,363 133 591 1.01 (0.84,1.22) 1.96 (1.50,2.56) 1.08 0.55
June  62,444 131 606 0.97 (0.81,1.18) 1.88 (1.44,2.46) 1.07 0.57
July  65,645 121 687 0.79 (0.65,0.96) 1.54 (1.17,2.01) 0.98 0.64
Aug  65,298 133 807 0.74 (0.62,0.89) 1.44 (1.11,1.87) 1.08 0.75
Sep  65,086 136 842 0.73 (0.61,0.87) 1.41 (1.09,1.83) 1.11 0.79
Oct  62,275 123 1072 0.51 (0.43,0.62) Reference 1.00 1.00
Nov  55,404 138 909 0.68 (0.57,0.82) 1.32 (1.02,1.71) 1.12 0.85
Dec  54,367 141 939 0.68 (0.57,0.81) 1.31 (1.01,1.69) 1.15 0.88 <0.0001
12-Month vaccination
Overall 625,255 8990 9516 1.70 (1.65,1.75) – – –
Jan  49,578 856 944 1.63 (1.49,1.79) 1.18 (1.02,1.35) 1.35 1.15
Feb  46,654 831 907 1.65 (1.50,1.81) 1.19 (1.03,1.37) 1.31 1.11
Mar  52,372 905 960 1.70 (1.55,1.86) 1.22 (1.06,1.40) 1.43 1.17
Apr  52,610 806 851 1.70 (1.55,1.88) 1.23 (1.07,1.41) 1.28 1.04
May  55,045 768 692 2.00 (1.80,2.21) 1.44 (1.24,1.66) 1.22 0.84
June  53,624 677 622 1.96 (1.76,2.18) 1.41 (1.21,1.64) 1.07 0.76
July  56,745 682 582 2.11 (1.89,2.36) 1.52 (1.30,1.77) 1.08 0.71
Aug  56,701 618 744 1.50 (1.34,1.66) 1.08 (0.93,1.25) 0.98 0.91
Sep  56,542 726 776 1.68 (1.52,1.86) 1.21 (1.05,1.40) 1.15 0.95
Oct  54,020 759 831 1.64 (1.49,1.81) 1.18 (1.03,1.37) 1.20 1.01
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 seasonal effect of susceptibility to AEFI. We  observed a strong
ffect of month of birth on the RI of ER visits and admissions. The
bserved effect was strongest at the 2-month vaccination, at which
he ﬁrst dose of the DTaP-IPV-Hib vaccine is given. For the 2-month
accination, we observed a greater than two-fold increase in the RI
f events for children born in April, compared to children born in
ctober, the month of the lowest RI of events. A clear sinusoidal
attern was observed between the month of birth and RI.
One of our sensitivity analyses suggested that an important
river of elevated RI was a decrease in incidence during the con-
rol period. This provides evidence that the background burden
f seasonal illness may  be another contributing factor to the sea-
onal effect we observed. During months of higher burden of illness
e.g. fall/winter) the incidence in the control period was higher as
ompared to the control period in months of lower burden (spring
nd summer). These ﬂuctuations in the background burden of ill-
ess may  have contributed to lower RIs in fall/winter and higher
Is in spring/summer either through access to care issues in the
all/winter (e.g. crowded ERs), or by making vaccine reactions less
ikely when infants are battling many other circulating infections.
nother possible explanation is that during the colder months in
ntario Canada, inclement weather and ER waiting rooms crowded
ith children suffering from inﬂuenza and common cold may  make
t less likely that a parent decides to visit an ER when their child is
uffering from a relatively mild post-vaccination reaction.
Since the correlation coefﬁcient between birth month and vac-
ination month was measured to exceed 0.99 for both of the 2-
nd 12-month vaccinations, due to well established immunization
chedules, we  performed additional analyses aimed at isolating the
ffect of month of vaccination as distinct from birth month. We
ound evidence suggesting that month of vaccination may  have
ontributed to the seasonal variation we observed in our results.
owever, in practice it would be extremely difﬁcult to completely
ease apart the independent effects of birth month and vaccination
onth.) Reference 1.00 1.00
) 1.20 (1.04,1.39) 1.16 0.96 <0.0001
The seasonal pattern we observed closely corresponds to
other reported seasonal patterns according by birth month for
a number of immune-mediated chronic diseases such as type
I diabetes, multiple sclerosis, ulcerative colitis, Crohn’s disease,
lupus and rheumatoid arthritis [8–11] (Supplementary Fig. 2). Evi-
dence exists to suggest that the seasonal patterns observed in
immune-mediated diseases may  be linked to sunlight exposure,
and more speciﬁcally ultraviolet (UV) irradiance [19]. Seasonal pat-
terns observed in the northern hemisphere have also been reported
in the southern hemisphere with reciprocal periodicity [20], and
have been shown to be muted or absent in more equatorial regions
[8]. As it is well established that UV radiation is an important con-
tributor to circulating vitamin D levels and plays a role in the
degradation of circulating folic acid, variations in sunlight expo-
sure by season or by latitude during sensitive periods of fetal and
perinatal development could inﬂuence immune system develop-
ment and maturation in early life, leading to variations in the risk
of immune-related problems and vaccine reactions [9,19–22]. Vari-
ations in UV exposure by birth month may  also inﬂuence the risk of
vaccine reactions through mechanisms involved in the acquisition
of immunity to vaccine-preventable diseases. Long-term immunity
is achieved through induction of antibodies generally produced by
B lymphocytes [23]. Also important in immune response are cyto-
toxic CD8+ and CD4+ T lymphocytes that may limit the spread of
infectious agents by targeting and killing infected cells. Both B and
T cell responses are triggered by vaccines and are involved in the
development and maintenance of long-term immunity [23]. There-
fore, exogenous environmental factors such as sunlight exposure
and vitamin D that inﬂuence B and T cell activity impact upon the
immediate immune-mediated physiological response to immune
challenges and therefore could plausibly impact upon rates of AEFI.
Thymic development, which is important for immune function, pri-
marily occurs in utero and is sensitive to intrauterine exposures.
One study reported that month of birth is associated with varia-
tions in thymic output, and that vitamin D may be a driver of this
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ffect [24]. It has also been shown in animal studies that vitamin
 deﬁciency in utero, which may  be inﬂuenced by maternal sun-
ight exposure, has a signiﬁcant impact on the developing immune
ystem of the fetus [25,26].
Our study has a number of strengths and limitations. Strengths
nclude the large population-based birth cohort, which included
irtually all births in Ontario, Canada, spanning nearly a decade,
epresenting over a million births and over 700,000 vaccinated
nfants. An additional strength of this study is our novel applica-
ion of the SCCS design and use of RIRs to compare RIs among
hildren born at different times of the year. An additional advantage
f using RIRs is that it can help to overcome the healthy vaccinee
ias since the bias is effectively canceled out when comparing dif-
erent subgroups each affected by the healthy vaccinee bias. On the
ther hand, the protection from confounding conferred by the SCCS
esign, does not necessarily provide protection from confounding
f RIR estimates.
A  potential limitation of our implementation of the SCCS design
as our use of short control periods. Many common applications
f the SCCS will deﬁne much broader control periods, including
eeks or months of observation time before and after the index
accination as part of the unexposed control period. Informed by
ur previous studies, we chose shorter control periods in order to:
1) reduce the impact of variations in background risk of events in
arly life, (2) reduce the impact of variations in background risk due
o seasonal effects, (3) reduce the chance of overlapping risk and
ontrol periods (due to multiple recommended vaccinations within
 short period of time) and (4) exclude (to the extent possible) the
eriods most affected by the healthy vaccinee bias [1,2]. Although
hese issues are typically addressed in the SCCS model through
tratiﬁcation by age, season and repeat vaccinations, this approach
ould have negated our ability to directly study the impact of sea-
onal variation on speciﬁc vaccinations.
Our use of admissions and ER visits as a proxy for AEFIs con-
titutes both a strength and weakness of our study. As strengths,
he use of overall health services outcomes allowed us to study
he comparative health system impact of children born at different
imes of year, and the broad event deﬁnition provided a large boost
n power and sample size. The negative aspect of this proxy vari-
ble was that it was less speciﬁc than direct assessment of AEFIs,
ut this was mitigated by our exclusion of events where a causal
ink was highly implausible.
Our ﬁndings suggest that the same seasonal effect of month of
irth that inﬂuences rates of a number of immune-mediated dis-
ases may  also affect susceptibility to adverse events following
accination. Whether our ﬁndings are attributable to birth month,
accination month or a combination of the two, and whether the
ackground rate of events are part of the explanation, will require
urther study. Future studies should focus on investigating the
ossible role of the biological and/or behavioral mechanisms we
ave described to explain the seasonal variation in adverse events
bserved following vaccination.
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